Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Rhythm Pharmaceuticals Inc (RYTM)
NASDAQ:RYTM
RESEARCH TOOLSreports
Rhythm Pharmaceuticals (RYTM) Stock Price & Analysis
408 Followers
RYTM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$15.50 - $52.57
Previous Close$37.96
Volume750.72K
Average Volume (3M)569.60K
Market Cap
$2.31B
Enterprise Value$2.02B
Total Cash (Recent Filing)$299.26M
Total Debt (Recent Filing)$1.44M
Price to Earnings (P/E)-8.2
Beta0.94
Next Earnings
Jul 30, 2024EPS Estimate
-$0.71Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.64
Shares Outstanding60,972,909
10 Day Avg. Volume626,143
30 Day Avg. Volume569,601
Standard Deviation0.35
R-Squared0.09
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)14.68
Price to Sales (P/S)97.92
Price to Cash Flow (P/CF)-20.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue48.33
Enterprise Value/Gross Profit93.78
Enterprise Value/Ebitda-16.02
Forecast
1Y Price Target
$57.50Price Target Upside51.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Rhythm Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Clinical Trial OutcomesIMCIVREE's Phase 3 trial is meaningfully de-risked, suggesting confidence in successful outcomes.
Market PenetrationImcivree is now available in 14 global markets, indicating expansion and market penetration.
Product LaunchPotential growth is expected from the hypothalamic obesity (HO) launch with an estimated $1bn peak sales.
Bears Say
Financial PerformanceSales impacted by state adding barriers to Medicaid reimbursement and sales lighter than modeled.
Market Access ChallengesOne state Medicaid program stopped covering Imcivree, impacting patient access to the drug.
Product LaunchManagement acknowledges launch will be slow and steady, not outsized as previously expected.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
RYTM FAQ
What was Rhythm Pharmaceuticals Inc’s price range in the past 12 months?
Rhythm Pharmaceuticals Inc lowest stock price was $15.50 and its highest was $52.57 in the past 12 months.
What is Rhythm Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is Rhythm Pharmaceuticals Inc’s upcoming earnings report date?
Rhythm Pharmaceuticals Inc’s upcoming earnings report date is Jul 30, 2024 which is in 72 days.
How were Rhythm Pharmaceuticals Inc’s earnings last quarter?
Rhythm Pharmaceuticals Inc released its earnings results on May 07, 2024. The company reported -$2.35 earnings per share for the quarter, beating the consensus estimate of -$2.356 by $0.006.
Is Rhythm Pharmaceuticals Inc overvalued?
According to Wall Street analysts Rhythm Pharmaceuticals Inc’s price is currently Undervalued.
Does Rhythm Pharmaceuticals Inc pay dividends?
Rhythm Pharmaceuticals Inc does not currently pay dividends.
What is Rhythm Pharmaceuticals Inc’s EPS estimate?
Rhythm Pharmaceuticals Inc’s EPS estimate is -$0.71.
How many shares outstanding does Rhythm Pharmaceuticals Inc have?
Rhythm Pharmaceuticals Inc has 60,972,908 shares outstanding.
What happened to Rhythm Pharmaceuticals Inc’s price movement after its last earnings report?
Rhythm Pharmaceuticals Inc reported an EPS of -$2.35 in its last earnings report, beating expectations of -$2.356. Following the earnings report the stock price went down -10.324%.
Which hedge fund is a major shareholder of Rhythm Pharmaceuticals Inc?
Among the largest hedge funds holding Rhythm Pharmaceuticals Inc’s share is PRIMECAP Management Co. It holds Rhythm Pharmaceuticals Inc’s shares valued at 336M.
---
Rhythm Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$57.50 (51.48% Upside)
$57.50 (51.48% Upside)
Blogger Sentiment
Bullish
RYTM Sentiment 66%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.4%
Last 30 Days ▲ 12.9%
Last 30 Days ▲ 12.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
130.47%
12-Months-Change
Fundamentals
Return on Equity
-194.68%
Trailing 12-Months
Asset Growth
-25.18%
Trailing 12-Months
Company Description
Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals, Inc. develops and commercializes peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. It focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. The firm rapidly develops setmelanotide for rare genetic disorders of obesity caused by MC4 pathway deficiencies and provides advance setmelanotide for POMC deficiency obesity and LEPR deficiency obesity as first indications in upstream MC4 pathway deficiencies. The company was founded by Bart Henderson in February 2010 and is headquartered in Boston, MA.
---
RYTM Company Deck
---
RYTM Earnings Call
Q1 2024
0:00 / 0:00
---
RYTM Stock 12 Month Forecast
Average Price Target
$57.50
▲(51.48% Upside)
Technical Analysis
Best Analysts Covering RYTM
1 Year
1 Year Success Rate
14/22 ratings generated profit
1 Year Average Return
+66.70%
reiterated a buy rating 12 days ago
Copying Joseph Stringer's trades and holding each position for 1 Year would result in 63.64% of your transactions generating a profit, with an average return of +66.70% per trade.
---